Dawn N. Waterhouse, Ph.D.

2002 University of British Columbia, Vancouver, Vancouver, BC, Canada 
Oncology, Animal Physiology Biology, Cell Biology
"Dawn Waterhouse"
Mean distance: (not calculated yet)


Sign in to add mentor
Marcel Bally grad student 2002 UBC
 (Antisense oligonucleotides as therapeutics for the treatment of aggressive breast cancer.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Waterhouse DN, Sutherland BW, Santos ND, et al. (2014) Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. Investigational New Drugs. 32: 1071-82
Hare JI, Neijzen RW, Anantha M, et al. (2013) Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. Plos One. 8: e62349
Waterhouse DN, Yapp D, Verreault M, et al. (2011) Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine (London, England). 6: 1645-54
Edwards LA, Woo J, Huxham LA, et al. (2008) Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Molecular Cancer Therapeutics. 7: 59-70
Chiu GN, Edwards LA, Kapanen AI, et al. (2007) Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Molecular Cancer Therapeutics. 6: 844-55
Waterhouse DN, Bally MB. (2006) Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy. Nanomedicine (London, England). 1: 359-63
Waterhouse DN, Gelmon KA, Klasa R, et al. (2006) Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Current Cancer Drug Targets. 6: 455-89
Waterhouse DN, Denyssevych T, Hudon N, et al. (2005) Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharmaceutical Research. 22: 915-22
Abraham SA, Waterhouse DN, Mayer LD, et al. (2005) The liposomal formulation of doxorubicin. Methods in Enzymology. 391: 71-97
Waterhouse DN, Madden TD, Cullis PR, et al. (2005) Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods in Enzymology. 391: 40-57
See more...